|
1）Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009; 135: 1550-6
|
|
|
|
2）Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibodypositive interstitial lung disease. Arthritis Rheum. 2009; 60: 2183-92
|
|
|
|
|
|
3）Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006; 39: 233-41
|
|
|
|
|
|
4）Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996; 26: 459-67
|
|
|
|
|
|
5）Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011; 105: 1380-7
|
|
|
|
|
|
6）Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003; 32: 273-84
|
|
|
|
|
|
7）Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001; 164: 1182-5
|
|
|
|
|
|
8）Meyer O, Charlanne H, Cherin P, et al. Subluxing arthropathy: an unusual manifestation of the anti-synthetase syndrome. Ann Rheum Dis. 2009; 68: 152-3
|
|
|
|
|
|
9）Krain L. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol. 1975; 111: 241-5
|
|
|
|
|
|
10）Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993; 100: 124S-127S
|
|
|
|
|
|
11）Sato S, Hirakata M, Kuwana M, et al. utoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52: 1571-6
|
|
|
|
|
|
12）Nakashima R, Imura Y, Mimori T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010; 49: 433-40
|
|
|
|
|
|
13）Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60: 2193-200
|
|
|
|
|
|
14）Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49: 1354-60
|
|
|
|
|
|
15）Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990; 33: 1361-70
|
|
|
|
|
|
16）Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012; 69: 728-32
|
|
|
|
|
|
17）Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999; 78: 139-47
|
|
|
|
|
|
18）Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991; 41: 936-9
|
|
|
|
|
|
19）Miller T, Al-Lozi MT, Lopate G, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002; 73: 420-8
|
|
|
|
|
|
20）Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985; 28: 796-803
|
|
|
|
|
|
21）Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009; 60: 2499-504
|
|
|
|
|
|
22）Mierau R, Dick T, Bartz-Bazzanella P, et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 1996; 39: 868-76
|
|
|
|
|
|
23）Seelig HP, Renz M, Targoff IN, et al. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum. 1996; 39: 1769-71
|
|
|
|
|
|
24）Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2 beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development. 2007; 134: 1571-82
|
|
|
|
|
|
25）Burd CJ, Kinyamu HK, Miller FW, et al. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem. 2008; 283: 34976-82
|
|
|
|
|
|
26）Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006; 54: 3682-9
|
|
|
|
|
|
27）Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007; 46: 25-8
|
|
|
|
|
|
28）Targoff IN, Trieu EP, Levy-Neto M, et al. Autoanti-bodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum. 2006; 54 Suppl: S518
|
|
|
|
|
|
29）Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target trans-cription intermediary factor 1 family proteins. Arthritis Rheum. 2012; 64: 513-22
|
|
|
|
|
|
30）Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a noncanonical histone signature to breast cancer. Nature. 2010; 468: 927-32
|
|
|
|
|
|
31）Wang C, Ivanov A, Chen L, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005; 24: 3279-90
|
|
|
|
|
|
32）Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti155/140 autoantibodies target trans-cription intermediary factor 1 family proteins. Arthritis Rheum. 2012; 64: 513-22
|
|
|
|
|
|
33）Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immunemediated necrotizing myopathy. Arthritis Rheum. 2010; 62: 2757-66
|
|
|
|
|
|
34）Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with statin associated autoimmune myopathy. Arthritis Rheum. 2011; 63: 713-21
|
|
|
|
|
|
35）Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1_11: 01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken). 2012; 64: 1233-7
|
|
|
|
|
|
36）Ichimura Y, Matsushita T, Fujimoto M, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012; 71: 710-3
|
|
|
|
|
|
37）Mimura Y, Takahashi K, Kawata K, et al. Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci. 2010; 123: 2014-24
|
|
|
|
|
|
38）Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012; 14: R97
|
|
|
|
|
|
39）Mimori T, Imura Y, Nakashima R, et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19: 523-9
|
|
|
|
|